Literature DB >> 29426407

Seroprevalence and risk factors for selected respiratory and reproductive tract pathogen exposure in European bison (Bison bonasus) in Poland.

Michał K Krzysiak1, Artur Jabłoński2, Wojciech Iwaniak3, Monika Krajewska3, Julia Kęsik-Maliszewska4, Magdalena Larska5.   

Abstract

After the complete extinction from the wild of European bison (Bison bonasus) at the beginning of the twentieth century, the worldwide species population was restored to approximately 5500 individuals, with the species however remaining endangered. Despite numerous studies on the ecology and genetics of European bison, the threats of infectious diseases have been largely unexamined. The aim of this study was to screen the exposure of the world's largest population of European bison to the pathogens, which may influence the condition and development of the endangered species. A total of 240 free-ranging and captive European bison from eight main Polish populations sampled were tested for the presence of specific antibodies against ten different viruses, bacteria or protozoan. The samples were collected from chemically immobilized, selectively culled or found dead animals. Based on serology, the exposure to bovine viral diarrhea virus (BVDV), bovine herpesvirus type 1 (BoHV-1), Mycoplasma and Brucella spp. was determined as rather accidental. Using gamma-interferon assay followed by Mycobacterium tuberculosis subs. caprae detection in tissues, diagnosis of bovine tuberculosis was made for 6 out of 78 (7.7%) bison from one captive herd. The highest seroprevalence was found for bovine adenovirus type 3 (BAdV-3) -60.2% and bovine parainfluenza type 3 (PIV-3) -34.0%, while the antibodies against bovine respiratory syncytial virus (BRSV), Toxoplasma gondii and Leptospira spp. were found in 10.4%, 10.4% and 8.7% of samples, respectively. In the multivariable statistical analysis using generalized linear mixed models (GLMMS), the risk factors for PIV-3 seropositivity included population type (free-living/captive), age and health status (apparently healthy/eliminated due to the poor condition). Higher risk of BAdV-3 seropositive result was observed in free-living female European bison. The high BAdV-3 and PIV-3 seroprevalences may suggest involvement of these pathogens in the most frequently observed respiratory disorders in European bison. Moreover, this is the first study demonstrating BAdV-3 exposure in the species.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BAdV-3; BRSV; BVDV; BoHV-1; Brucella spp.; European bison; Leptospira spp.; Mycobacterium spp.; Mycoplasma spp.; PIV-3; Toxoplasma gondii

Mesh:

Year:  2018        PMID: 29426407     DOI: 10.1016/j.vetmic.2018.01.005

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  4 in total

1.  The Nematodes Thelazia gulosa Railiet and Henry, 1910 and Thelazia skrjabini Erschov, 1928 as a Cause of Blindness in European Bison (Bison bonasus) in Poland.

Authors:  Aleksander W Demiaszkiewicz; Bożena Moskwa; Aneta Gralak; Zdzisław Laskowski; Anna W Myczka; Marta Kołodziej-Sobocińska; Stanisław Kaczor; Elwira Plis-Kuprianowicz; Michał Krzysiak; Katarzyna Filip-Hutsch
Journal:  Acta Parasitol       Date:  2020-07-01       Impact factor: 1.440

2.  The First Report of Immunoglobulin G, M, and A Concentrations in Serum of European Bison and Their Changes with Age.

Authors:  Małgorzata Pomorska-Mól; Michał K Krzysiak; Magdalena Larska; Jan Włodarek
Journal:  J Immunol Res       Date:  2020-01-23       Impact factor: 4.818

3.  Infection with Foamy Virus in Wild Ruminants-Evidence for a New Virus Reservoir?

Authors:  Magdalena Materniak-Kornas; Martin Löchelt; Jerzy Rola; Jacek Kuźmak
Journal:  Viruses       Date:  2020-01-03       Impact factor: 5.048

4.  Detection of treponemes in digital dermatitis lesions of captive European bison (Bison bonasus).

Authors:  Stefan Hoby; Tim K Jensen; Isabelle Brodard; Corinne Gurtner; Richard Eicher; Adrian Steiner; Peter Kuhnert; Maher Alsaaod
Journal:  PLoS One       Date:  2021-08-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.